Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04825678 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
A Phase 4 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 240
- Enrollment target
NCT04825678 is a Phase 4 study that has completed, run by Amgen. The registered enrollment target is 240 participants.
The verdict
NCT04825678, a Phase 4 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 240 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.
Interventions
- DRUG Erenumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2023-09-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04825678
The ClinicalTrials.gov registry entry for NCT04825678 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Erenumab is the first listed.
NCT04825678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04825678 about?
NCT04825678 is a clinical study titled "A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine". The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.
What is the current status of trial NCT04825678?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 240 participants. The study started on 2021-06-11. Estimated completion is 2023-09-28.
What interventions are being tested in trial NCT04825678?
The interventions under investigation include: Erenumab (DRUG).
Who is sponsoring clinical trial NCT04825678?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.